Further studies are also needed to assess whether therapies targeting against fibroblast activation, such as inhibitors of FGFR1 or STAT3, may potentially benefit severely ill COVID-19 patients at risk for or with cardiac microthrombi. The gene discussed is FGFR1; the disease is COVID-19.